Table 3.
Univariate and Multivariate Analyses of Predictive Baseline Factors for Hemagglutination Inhibition Titers ≥ 1:40 at Day 21 After Vaccination
| Variable | No. of patients | Univariate analysis OR (95% CI)a | Pb | Multivariate analysis OR (95% CI)a | Pb |
| Male vs female | 299 | 1.218 (0.564–2.627) | .62 | ||
| Age <40 years | 299 | 1.676 (0.744–3.778) | .21 | 1.153 (.469–2.834) | .76 |
| Smoker | 299 | 0.859 (0.450–1.638) | .64 | ||
| CDC stage C | 299 | 0.907 (0.481–1.711) | .76 | ||
| HCV and/or HBV coinfection | 298 | 0.326 (0.150–.706) | .005 | 0.259 (.109–.617) | .002 |
| Nadir CD4+ cell count, per 50 cells/mm3 higher | 299 | 1.069 (0.977–1.171) | .15 | 0.976 (.875–1.089) | .66 |
| Baseline CD4+ cell count, ≥350/mm3 | 298 | 1.182 (0.532–2.629) | .68 | ||
| Seasonal influenza vaccination | 299 | 1.297 (0.610–2.757) | .50 | ||
| HAART vs without HAART | 299 | 0.281 (0.097–.815) | .02 | 0.444 (.025–7.924) | .58 |
| Baseline plasma HIV-1 viral load, log10 copies/mL | 299 | 1.601 (1.062–2.416) | .024 | 1.251 (.426–3.672) | .68 |
| AS03A adjuvanted vsnonadjuvanted H1N1v vaccine | 299 | 4.605 (2.190–9.685) | <.001 | 5.331 (2.439–11.65) | <.001 |
NOTE. CDC, Centers for Disease Control and Prevention; CI, confidence interval; HAART, highly active antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; OR, odds ratio.
a
Wald confidence interval.
b
Wald χ2 P value.